Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 3 June 2019, 21:00 HKT/SGT
Share:
    

Source: Proteomics International Laboratories Ltd (PILL)
Proteomics International and PromarkerD at BIO 2019 saying 30 million diabetics in US deserve to know their future kidney disease status
- PromarkerD world's leading diagnostic test for diabetic kidney disease says Frost & Sullivan industry report 'Biomarkers Enabling Diabetes and Obesity Management'

Philadelphia, PA, June 3, 2019 - (ACN Newswire) - Proteomics International (PILL; ASX: PIQ) will be at the 2019 BIO International Convention in Philadelphia (stand #2349) preparing for the US roll-out of PromarkerD, a blood test that can diagnose and predict whether a healthy patient will develop diabetic kidney disease.

"PromarkerD is world-beating technology and needs to get into the hands of specialists and physicians to stem the tsunami of kidney disease which is causing over 40,000 deaths per year in the US, with related healthcare spending exceeding US$100 billion annually."

"There is nothing else like PromarkerD available - it's the world's leading predictive test for diabetic kidney disease according to analysts in our sector," said Chuck Morrison, Proteomics International's Head of Business Development, based in Boston. "The US population with diabetes deserve to know their kidney disease status."

He said the test will also make a major difference for insurance companies because it will cut dramatically the number of people who are unaware they have progressive kidney disease so they can do something about it immediately, and so reduce treatments costs.

PromarkerD, rated the world's leading diagnostic test for diabetic kidney disease by Frost & Sullivan in its independent industry report titled 'Biomarkers Enabling Diabetes and Obesity Management', has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending.

The Australian delegation to BIO 2019 is the largest to date, and is among the ten largest this year, alongside 17,000 biotech and pharma leaders from 70 countries. The Western Australian 'Think Perth' delegation is led by the State's Deputy Premier and Minister for Health, Hon Roger Cook, and Professor Peter Klinken, Chief Scientist of Western Australia.

PromarkerD (www.PromarkerD.com)

PromarkerD is a predictive diagnostic test for diabetic kidney disease. In clinical studies presented at the American Diabetes Association Annual Scientific Sessions [ASX: 13 June 2017] and published in the journal Diabetes Care [ASX: 6 Sept 2017], PromarkerD correctly predicted 86% of previously kidney disease-free diabetic patients who went on to develop chronic kidney disease.

PromarkerD has been rated the world's leading diagnostic test for diabetic kidney disease by global research house Frost & Sullivan in its report 'Biomarkers Enabling Diabetes and Obesity Management' [ASX: 27 March 2017]. PromarkerD has received patent protection in several major jurisdictions including the USA, China, Europe, and Japan, with others pending. Further information is available at the PromarkerD web portal.

Proteomics International (www.proteomicsinternational.com)

Proteomics International Laboratories Ltd ('PILL'; ASX: PIQ) is a medtech company at the forefront of predictive diagnostics and bio-analytical services, focused on proteomics - the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities on QEII Medical Campus in Perth, W. Australia.

Proteomics International is centred on commercialisation of its world-leading test for diabetic kidney disease, PromarkerD. The company offsets its R&D and product development cash flows with provision of specialist analytical services, while using its proprietary Promarker(TM) technology to create a pipeline of novel diagnostic tests.

Please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: [email protected]

Chuck Morrison
Head of Business Development
Proteomics International
T: +1 617 331 2975
E: [email protected]

Susan Fitzpatrick-Napier
Public Relations & Media Contact
Digital Mantra Group
T: +61 2 8218 2144 or +1 415 951 3228
E: [email protected]

Dirk van Dissel
Corporate Advisor & Investor Relations
Adelaide Equity Partners
T: +61 8 8232 8800
E: [email protected]


June 3, 2019 21:00 HKT/SGT
Topic: Trade Show or Conference
Sectors: BioTech, HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Proteomics International Laboratories Ltd (PILL)
June 7, 2019 12:00 HKT/SGT
PromarkerD features at American Diabetes Association 79th Scientific Sessions saying diabetics deserve to know their future kidney disease status
June 4, 2018 11:00 HKT/SGT
Proteomics International signs with PrismHealthDx for US launch of PromarkerD predictive test for diabetic kidney disease
Mar 20, 2018 05:00 HKT/SGT
PromarkerD Diagnostic Test Leader Officially Launched
Feb 12, 2018 06:00 HKT/SGT
Proteomics International announces Strategic Alliance and Investment in CPR Pharma Services
June 12, 2017 08:00 HKT/SGT
Clinical Validation Results confirm PromarkerD can predict Diabetic Kidney Disease better than any Current Measure
Mar 28, 2017 18:00 HKT/SGT
Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease
Mar 27, 2017 16:00 HKT/SGT
Frost & Sullivan independent industry report identifies PromarkerD as the world leading test for Diabetic Kidney Disease
Mar 22, 2017 15:00 HKT/SGT
PromarkerD Predictive Diagnostics for DKD to Roll-out in Asia
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: